BioSpace News Archive

Business

Innate Pharma Reports First Half 2022 Financial Results and Business Update

Innate Pharma SA reported its consolidated financial results for the six months ended June 30, 2022. The consolidated financial statements are attached to this press release.

September 15, 2022
·
39 min read
Business

Oxford Biomedica plc Interim Results for the Six Months Ended 30 June 2022

Oxford Biomedica plc, a leading gene and cell therapy group, announces interim results for the six months ended 30 June 2022.

September 15, 2022
·
94 min read
FDA

Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma

Kymera Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL).

September 15, 2022
·
5 min read
BioCapital

Alphyn Biologics Closes $3.3 Million Series A Financing to Advance Breakthrough Atopic Dermatitis Treatment

Alphyn Biologics , a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it is has closed a Series A financing round of approximately $3.3 million.

September 15, 2022
·
3 min read
Business

Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz

Pasithea Therapeutics Corp. today announced the appointment of Dr. Merit Cudkowicz to its Scientific Advisory Board.

September 15, 2022
·
3 min read
Profound Medical Announces Changes to its Commercial Organization to Support Continued Growth

Profound Medical Corp. announced changes to its management team and structure designed to further position the Company for continued sales success and global growth.

September 15, 2022
·
5 min read
Genetown

Candel Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for CAN-2409 in Glioma

Candel Therapeutics, Inc. today announced that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion on the Company’s application for orphan drug designation for CAN-2409 for the treatment of glioma.

September 15, 2022
·
6 min read
Business

Infectious Disease Expert Pardis Sabeti, M.D., Ph.D. Joins Board of The 221b Foundation

The 221b Foundation, a non-profit founded by Sherlock Biosciences to bring novel CRISPR-based diagnostics to underserved populations around the world, today announced that Dr. Pardis Sabeti has joined its Board of Directors.

September 15, 2022
·
3 min read
Business

Excision Medical Inc. Announces $2.5M Funding and Two Important Additions to its Scientific Advisory Board

Excision Medical, Inc. announced today that it has raised a $2.5M financing led by the internal team, and added Drs. James McCabe , MD (UW Medicine, Seattle, WA ) and Adam Greenbaum, MD (Emory, Atlanta, GA) as Scientific Advisory Board members.

September 15, 2022
·
3 min read
BioMidwest

Surgalign Announces Third Clinical Site in the Commercialization of its HOLO Portal™ Surgical Guidance System

Surgalign Holdings, Inc. today announced further advancement in the commercialization of its HOLO Portal™ surgical guidance system.

September 15, 2022
·
4 min read